Humacyte Targets November 2026 FDA Filing for Dialysis Access Indication — Humacyte, Inc.

Event summary

Humacyte plans to file a supplemental BLA for ATEV in dialysis access in November 2026, following FDA discussions.
Phase 3 V012 study showed ATEV provided women with 3 additional months without dialysis catheters compared to standard AV fistula.
Supplemental BLA supported by data from three Phase 3 studies, including V007 and V006 in male and female dialysis patients.
ATEV aims to address unmet needs in dialysis access, particularly for patients with small vessel anatomy or complications.

The big picture

Humacyte's push for a second FDA approval for ATEV in dialysis access comes as the company seeks to expand its commercial footprint beyond vascular trauma. The move aligns with broader industry trends toward bioengineered solutions for chronic conditions, particularly in underserved patient populations. With nearly 500,000 Americans dependent on hemodialysis, the potential market for ATEV is substantial, though competition and reimbursement dynamics remain key hurdles.

What we're watching

Regulatory Pathway: Whether the FDA will expedite approval given the RMAT and Fast Track designations for ATEV.
Market Adoption: The pace at which ATEV could displace AV fistula as the standard of care in dialysis access.
Commercialization Strategy: How Humacyte plans to scale manufacturing to meet demand if approved for dialysis access.